Brugha, Rossa;
Kirkham, Amanda;
Bate, Jessica;
Burke, GA Amos;
Hughes, Ana;
Magwaro, Sophia;
Pope, Ann M;
... OCTAVE-Minor Collaborative Groupˆ; + view all
(2025)
SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.
Journal of Pediatrics
, Article 114873. 10.1016/j.jpeds.2025.114873.
Preview |
Text
1-s2.0-S0022347625004147-main.pdf - Accepted Version Download (2MB) | Preview |
Abstract
OBJECTIVE: To investigate the concern that children and young people (CYP) receiving immune-suppressing treatments mount impaired responses to vaccines, in CYP compared with healthy controls. STUDY DESIGN: We prospectively enrolled CYP aged 5-17 years who are receiving we measured humoral and cellular biological response modifying (BRM) therapies for rheumatologic inflammatory conditions (RIC), or post solid organ transplant (PSOT), or cancer chemotherapy before and/or after routine vaccinations with BNT162b2 vaccine. Responses to SARS-CoV-2 vaccination were assessed by anti-SARS-CoV-2 spike antibodies (Roche Diagnostics) and T-cell responses (Oxford Immunotec). Response to wild-type and SARS-CoV-2 variants (BA.5, XBB1.5) was assessed by microneutralization assay. Control data were from ComCOV3. RESULTS: 125 eligible participants enrolled (RIC n=54 [43·2%], PSOT n=49 [39·2%], cancer n=22 [17·6%]); 58 (46·4%) female; mean (SD) age 12·9 (2·9) years. 79 (63·2%) participants had prior COVID-19 and 28 (22·4%) were unvaccinated prior to study; 97 (77·6%) participants received one or more vaccines; 13 (10·4%) reported COVID-19 infection during follow up. CYP receiving chemotherapy for cancer had lower antibody responses post vaccine: anti-SARS-CoV-2 spike antibodies (median [IQR], AU/mL) = 26·7 [2·3-1088·0] compared with RIC = 6970·0 [1417·0-18163·0] and PSOT = 7899·0 [1711·0-19201·0]), both p values <0·0001. T-cell responses (median [IQR] SFC/106 PBMCs) were also reduced in the cancer group (8.0 [0·0-48.0]) compared with RIC (110.0 [44.0-260.0]) p=0.009 and PSOT (74.0 [32·0-160·0]), p=0·003. CONCLUSIONS: Children receiving immune-suppressing therapies for RIC and PSOT had antibody and T-cell responses after the third vaccine dose that approached levels reported in healthy controls. Children who were receiving cancer chemotherapy, however, showed substantially reduced humoral and T-cell responses.
| Type: | Article |
|---|---|
| Title: | SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jpeds.2025.114873 |
| Publisher version: | https://doi.org/10.1016/j.jpeds.2025.114873 |
| Language: | English |
| Additional information: | Under a Creative Commons license https://creativecommons.org/licenses/by/4.0/ |
| Keywords: | OCTAVE-Minor Collaborative Groupˆ |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10216737 |
Archive Staff Only
 |
View Item |
